In gastric cancer, two phase III KEYNOTE-585 (NCT03221426) and MATTERHORN (NCT04592913) trials to evaluate adding anti-PD-1/PD-L1 to chemotherapy in a perioperative setting are ongoing. The gene discussed is PDCD1; the disease is gastric cancer.